Overview

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

Status:
Completed

Trial end date:
2017-02-01

Target enrollment:

Participant gender:

Summary

This study will assess the bioequivalence (BE) of Lesinurad/Allopurinol Fixed-Dose Combination (FDC) Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects

Phase:

Phase 1

Details

Lead Sponsor:

Ardea Biosciences, Inc.

Treatments:

Allopurinol
Lesinurad